Back to Journals » Journal of Asthma and Allergy » Volume 9

Anti-inflammatory dosing of theophylline in the treatment of status asthmaticus in children

Authors Eid N, O'Hagan A, Bickel S, Morton R, Jacobson S, Myers J

Received 28 May 2016

Accepted for publication 9 August 2016

Published 13 October 2016 Volume 2016:9 Pages 183—189

DOI https://doi.org/10.2147/JAA.S113747

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Amrita Dosanjh


Nemr S Eid,1 Adrian O’Hagan,1 Scott Bickel,1 Ronald Morton,1 Sarah Jacobson,2 John A Myers3

1Division of Pediatric Pulmonology, University of Louisville, 2Department of Pharmacy, Kosair Children’s Hospital, 3Department of Pediatrics, University of Louisville, Louisville, KY, USA

Background: Low-dose theophylline has been recognized for its ability to restore histone deacetylase-2 activity which leads to improved steroid responsiveness and thus improved clinical outcome. We retrospectively evaluated the effect of low-dose theophylline therapy in pediatric patients hospitalized for an acute asthma exacerbation as a proof of concept study.
Methods: We compared patients who received low-dose theophylline (5–7 mg/kg/day) in addition to current standard of care to patients who were treated with current standard of care alone. The primary outcome of the study was hospital length of stay (LOS). Generalized linear mixed-effects modeling (GLMM) was used to test whether receiving theophylline independently predicted outcomes. A Cox (proportional hazards) regression model was also developed to examine whether theophylline impacted LOS.
Results: After adjustment for illness severity measures, theophylline significantly reduces LOS (β=–21.17, P<0.001), time to discontinue oxygen (β=–15.88, P=0.044), time to spirometric improvement (β=–16.60, P=0.014), and time to space albuterol (β=–23.2, P<0.001) as well as reduced costs (β=–US$2,746, P<0.001). Furthermore, theophylline significantly increased the hazards of being discharged from the hospital (hazards ratio =1.75, 95% confidence interval 1.20–2.54, P=0.004). There was no difference in side effects between patients who receive low-dose theophylline and those who did not.
Conclusion: The results of this retrospective study suggest low-dose theophylline may have a positive effect in acute status asthmaticus. This study suggests that further research with a prospective, randomized, double-blinded, placebo controlled trial may be warranted to confirm and extend our findings.

Keywords: theophylline, pediatric asthma, HDAC2, status asthmaticus

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]